Andrew Conery

Andrew Conery has extensive work experience in the biotechnology and biomedical research fields. Andrew is currently working as the Senior Director at TRIANA Biomedicines since January 2022. Prior to that, they held various roles at Constellation Pharmaceuticals, starting as a Scientist II in February 2010 and rising through the ranks to become the Senior Director of Functional Genomics. Their tenure at Constellation Pharmaceuticals spanned from July 2018 to April 2022.

Before joining Constellation Pharmaceuticals, Andrew worked at Harvard Medical School as an American Cancer Society Postdoctoral Fellow from January 2005 to February 2010. During this time, they conducted research on changes in ploidy during early lung tumor development and discovered the role of a tumor suppressor in regulating genomic stability. Andrew also served as a Postdoctoral Fellow at Harvard Medical School.

Furthermore, Andrew has a strong academic background. Andrew obtained their HHMI Predoctoral Fellowship from the University of California, Berkeley, where their research focused on the crosstalk between the TGF-beta and Akt signaling pathways in apoptosis. Andrew completed their Honors Thesis project at Case Western Reserve University, where they examined the oligomerization state of enoyl-CoA hydratase. Additionally, they worked as an ASPET Summer Research Intern at the University of Pittsburgh, where they identified a synergistic effect between topoisomerase II inhibitor etoposide and Gleevec in human leukemia cells.

Andrew Conery earned a Bachelor of Science degree in Biochemistry from Case Western Reserve University, where they studied from 1995 to 1999. Subsequently, they pursued their Ph.D. in Molecular Cell Biology at the University of California, Berkeley, completing their studies in 2004.